Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 10, 2004, Pages 2433-2437

  White, Alex W ^a   Curtin, Nicola J ^b   Eastman, Brian W ^c   Golding, Bernard T ^a   Hostomsky, Zdenek ^c   Kyle, Suzanne ^b   Li, Jianke ^c   Maegley, Karen A ^c   Skalitzky, Donald J ^c   Webber, Stephen E ^c   Yu, Xiao Hong ^c   Griffin, Roger J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Benzimidazole 4 carboxamides; Chemopotentiation; Inhibitors; PARP 1

Indexed keywords

AMINE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TEMOZOLOMIDE;

ARTICLE; CANCER CELL CULTURE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA METHYLATION; DRUG ACTIVITY; DRUG POTENTIATION; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL;

AMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DACARBAZINE; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 11144355069     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.03.017     Document Type: Article

References (23)

1. For recent reviews see: Jacobson M.K., Jacobson E.L. Trends Biochem. Sci. 24:1999;415-417.
2. Shall S., de Murcia G. Mutat. Res. 460:2000;1-15.
3. Smith S. Trends. Biochem. Sci. 26:2001;174-179.
4. Dantzer F., Schreiber V., Niedergang C., Trucco C., Flatter E., De La Rubia G., Oliver J., Rolli V., Menissier de Murcia J., de Murcia G. Biochemie. 81:1999;69-75.
5. de Murcia G., Menissier de Murcia J. Trends Pharmacol. Sci. 19:1994;172-176.
6. Herceg Z., Wang Z.Q. Mutat. Res. 477:2001;97-110.
7. Ame J.-C., Jacobson E.L., Jacobson M.K. de Murcia G., Shall S. From DNA Damage and Stress Signaling to Cell Death. 2000;1-22 Oxford University Press.
8. Chiarugi C. Trends Pharmacol. Sci. 23:2002;122-129.
9. Virág L., Szabó C. Pharmacol. Rev. 54:2002;375-429.
10. Griffin R.J., Curtin N.J., Newell D.R., Golding B.T., Durkacz B.W., Calvert A.H. Biochemie. 77:1995;408-422.
11. Bowman K.J., White A.W., Golding B.T., Griffin R.J., Curtin N.J. Br. J. Cancer. 78:1998;1269-1277.
12. Delaney C.A., Wang L.-Z., Kyle S., White A.W., Calvert A.H., Curtin N.J., Durkacz B.W., Hostomsky Z., Newell D.R. Clin. Can. Res. 6:2000;2860-2867.
13. White A.W., Almassey R., Calvert A.H., Curtin N.J., Griffin R.J., Hostomsky Z., Maegley K., Newell D.R., Srinivasan S., Golding B.T. J. Med. Chem. 43:2000;4084-4097.
14. Skalitzky D.J., Marakovits J.T., Maegley K.A., Ekker A., Yu X.-H., Hostomsky Z., Webber S.E., Eastman B.W., Almassy R., Li J., Curtin N.J., Newell D.R., Calvert A.H., Griffin R.J., Golding B.T. J. Med. Chem. 46:2003;210-213.
15. Canan Koch S.S., Thoresen L.H., Tikhe J.G., Maegley K.A., Almassy R.J., Li J., Yu X., Zook S.E., Kumpf R.A., Zhang C., Boritzki T.J., Mansour R.N., Zhang K.E., Ekker A., Calabrese C.R., Curtin N.J., Kyle S., Thomas H.D., Wang L.-Z., Calvert A.H., Golding B.T., Griffin R.J., Newell D.R., Webber S.E., Hostomsky Z. J. Med. Chem. 45:2002;4961-4974.
16. Higgins J., Marvel C.S. J. Polym. Sci, Part A-1. 8:1970;171-177.
17. Austen S.C., Kane J.M. J. Heterocyclic Chem. 38:2001;979-980.
18. Ackerley N., Brewster A.G., Brown G.R., Clarke D.S., Foubister A.J., Griffin S.J., Hudson J.A., Smithers M.J., Whittamore P.R.O. J. Org. Chem. 38:1995;1608-1628.
19. A general procedure for the synthesis of benzimidazole-4-carboxamides 7 and 8 is as follows: To a suspension of 2,3-diaminobenzamide (0.5 g) and sodium hydrogen sulfite (1.5 mol equivalents) in N,N-dimethylacetamide (10 mL/g), was added the appropriate aryl aldehyde (1 mol equivalent) dropwise over 15 min. After heating the reaction mixture for 5 h at 140°C with vigorous stirring, water (200 mL) was added, and the mixture was stirred for a further 2 h. The product was collected by filtration, and washed thoroughly with water.
20. 1H NMR, IR, UV) and analytical (elemental analysis and/or LC-MS) data fully consistent with the assigned structures.
21. Griffin R.J., Srinivasan S., White A.W., Bowman K., Calvert A.H., Curtin N.J., Newell D.R., Golding B.T. Pharm. Sci. 2:1996;43-47.
22. Exponentially growing cells were seeded into 96 well plates, drugs dissolved in DMSO were added to the culture medium such that the final DMSO concentration was 1%. Data were normalised to 1% DMSO alone control, or 0.4 μM PARP inhibitor alone, as appropriate.
23. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. J. Natl. Cancer. Inst. 82:1990;1107-1112.